Arun Menawat, CEO of Profound Medical (NASDAQ:PROF; TSX:PRN), was one of three nominees for the 2020 Bloom Burton award, which honors an individual who has made the most significant contribution to Canada’s innovative healthcare industry.
As one of Canada’s most successful medical device leaders, Dr. Menawat is being nominated for his banner year at Profound Medical. Last year, the company’s TULSA-PRO prostate cancer ablation system met all efficacy and key safety endpoints in a pivotal trial, leading to FDA 510(k) clearance and Health Canada approval. Profound is now commercializing TULSA-PRO in the U.S.
Other nominees include Gordon Keller, co-founder of BlueRock Therapeutics and Simon Pimstone, president and CEO, of Xenon Pharmaceuticals. The Bloom Burton award will be presented on Sept. 24.
